Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022

Table of Contents

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKET COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATION 19
1.6 MARKET STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 21

2.1 SECONDARY DATA 22
2.2 PRIMARY DATA 23
2.3 KEY INDUSTRY INSIGHTS 24
2.4 MARKET SIZE ESTIMATION 25
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 28
2.6 MARKET SHARE ESTIMATION 29
2.7 ASSUMPTIONS FOR THE STUDY 29

3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 34

4.1 OVERVIEW OF THE VACCINES MARKET 34
4.2 VACCINES MARKET, BY TYPE, 2017–2022 35
4.3 VACCINES MARKET, BY END USER, 2017 VS. 2022 (USD BILLION) 35
4.4 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY 36
4.5 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017 VS. 2022 (USD BILLION) 37
4.6 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 37

5 MARKET OVERVIEW 38

5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 High prevalence of infectious diseases 40
5.2.1.2 Rising focus on immunization programs 40
5.2.1.3 Growing government support for vaccine development 41
5.2.1.4 Increasing company investments into vaccine R&D 42
5.2.2 RESTRAINTS 43
5.2.2.1 High cost of vaccine development 43
5.2.2.2 Product Recalls 43
5.2.3 OPPORTUNITIES 44
5.2.3.1 High growth prospects in emerging markets 44
5.2.3.2 Focus on therapeutic vaccines 44
5.2.3.3 Use of adjuvants in vaccines 44
5.2.4 CHALLENGES 45
5.2.4.1 Inadequate access to vaccines 45
5.2.5 BURNING ISSUES 45
5.2.5.1 Vaccine pricing 45

6 INDUSTRY INSIGHTS 46

6.1 INVESTMENT ANALYSIS 46
6.2 REGULATORY LANDSCAPE 48
6.2.1 NORTH AMERICA 49
6.2.2 EUROPE 50
6.2.3 ASIA 50
6.2.4 ROW 51
6.3 KEY PIPELINE PRODUCTS 52
6.4 NEW VACCINE OPPORTUNITIES 53
6.4.1 HIV 53
6.4.1.1 HIV vaccine: Product pipeline 53
6.4.1.2 HIV vaccine: Public-private initiatives 54
6.4.1.3 HIV vaccine: Funding 54
6.4.2 MALARIA 56
6.4.2.1 Malaria vaccine: Product pipeline 56
6.4.2.2 Malaria vaccine: Public-private initiatives 57
6.4.3 ZIKA 57
6.4.3.1 Zika vaccine: Product pipeline 57
6.4.3.2 Zika vaccine: Public-private initiatives 57
6.4.3.3 Zika vaccine: Funding 58
6.4.4 EBOLA 58
6.4.4.1 Ebola vaccine: Product pipeline 58
6.4.4.2 Ebola vaccine: Public-private initiatives 59
6.4.4.3 Ebola vaccine: Funding 59

7 VACCINES MARKET, BY TECHNOLOGY 60

7.1 INTRODUCTION 61
7.2 CONJUGATE VACCINES 62
7.3 INACTIVATED AND SUBUNIT VACCINES 63
7.4 LIVE ATTENUATED VACCINES 65
7.5 RECOMBINANT VACCINES 66
7.6 TOXOID VACCINES 67

8 VACCINES MARKET, BY TYPE 68

8.1 INTRODUCTION 69
8.2 MONOVALENT VACCINES 70
8.3 MULTIVALENT VACCINES 71

9 VACCINES MARKET, BY DISEASE INDICATION 73

9.1 INTRODUCTION 74
9.2 PNEUMOCOCCAL DISEASE 75
9.3 DTP 76
9.4 INFLUENZA 77
9.5 HUMAN PAPILLOMA VIRUS 78
9.6 MENINGOCOCCAL DISEASE 80
9.7 POLIO 81
9.8 ROTAVIRUS 83
9.9 HEPATITIS 84
9.10 MMR 85
9.11 VARICELLA 86
9.12 DENGUE 87
9.13 OTHER DISEASE INDICATIONS 88

10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 90

10.1 INTRODUCTION 91
10.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 92
10.3 ORAL ADMINISTRATION 93
10.4 OTHER ROUTES OF ADMINISTRATION 94

11 VACCINES MARKET, BY END USER 95

11.1 INTRODUCTION 96
11.2 PEDIATRICS 97
11.3 ADULTS 98

12 VACCINES MARKET, BY REGION 100

12.1 INTRODUCTION 101
12.2 NORTH AMERICA 101
12.2.1 U.S. 105
12.2.2 CANADA 106
12.3 EUROPE 108
12.3.1 GERMANY 112
12.3.2 U.K. 113
12.3.3 FRANCE 114
12.3.4 ITALY 115
12.3.5 SPAIN 116
12.3.6 REST OF EUROPE (ROE) 117
12.4 ASIA 118
12.4.1 JAPAN 122
12.4.2 CHINA 123
12.4.3 INDIA 124
12.4.4 REST OF ASIA (ROA) 125
12.5 REST OF THE WORLD (ROW) 126

13 COMPETITIVE LANDSCAPE 130

13.1 INTRODUCTION 130
13.2 MARKET SHARE ANALYSIS 130
13.3 COMPETITIVE LEADERSHIP MAPPING 132
13.3.1 VISIONARY LEADERS 132
13.3.2 INNOVATORS 132
13.3.3 DYNAMIC DIFFERENTIATORS 132
13.3.4 EMERGING COMPANIES 132
13.4 STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS) 134
13.5 BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS) 135
*Top 25 companies analyzed for this studies are - Pfizer, Inc., GlaxoSmithKline plc., Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC, Astellas Pharma Inc., Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Science Corporation, Daiichi Sankyo Company, Limited, Abbott Laboratories, Panacea Biotec, PaxVax, Inc., Zydus Cadila, Green Cross Corporation, Valneva SE, Indian Immunologicals Limited, Incepta Vaccine Ltd., Sinovac Biotech Ltd., VBI Vaccines Inc., PT Bio Farma (Persero)

14 COMPANY PROFILES 136

(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
14.1 PFIZER, INC. 136
14.2 GLAXOSMITHKLINE PLC. 141
14.3 MERCK & CO., INC. 146
14.4 SANOFI PASTEUR SA 150
14.5 CSL LIMITED 155
14.6 EMERGENT BIOSOLUTIONS, INC. 159
14.7 JOHNSON & JOHNSON 164
14.8 MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA) 168
14.9 ASTELLAS PHARMA, INC. 171
14.10 SERUM INSTITUTE OF INDIA 174
14.11 BAVARIAN NORDIC 177
14.12 MITSUBISHI TANABE PHARMA CORPORATION 182
14.13 DAIICHI SANKYO COMPANY, LIMITED 185
14.14 PROTEIN SCIENCES CORPORATION 189
14.15 PANACEA BIOTEC 193

*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.
15 APPENDIX 196

LIST OF TABLES

TABLE 1 INCIDENCE OF DISEASES, 2015 40
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2012-2017 (USD MILLION) 42
TABLE 3 IMMUNIZATION COVERAGE, BY DISEASE, 2014 VS 2015 45
TABLE 4 REGULATORY AUTHORITIES IN EUROPE 50
TABLE 5 REGULATORY AUTHORITIES IN ASIA 51
TABLE 6 KEY PIPELINE VACCINES 52
TABLE 7 ESTIMATED INVESTMENT IN HIV VACCINES, BY INVESTOR (2015–2016) 55
TABLE 8 EBOLA PROJECTS FUNDED BY EUROPEAN COMMISSION (2014–2020) 59
TABLE 9 VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 61
TABLE 10 COST OF MENINGOCOCCAL CONJUGATE VACCINES 62
TABLE 11 CONJUGATE VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 62
TABLE 12 EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES 64
TABLE 13 INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION,
2015–2022 (USD MILLION) 64
TABLE 14 LIVE ATTENUATED VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 65
TABLE 15 EXAMPLES OF RECOMBINANT VACCINES 66
TABLE 16 RECOMBINANT VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 66
TABLE 17 TOXOID VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 67
TABLE 18 VACCINES MARKET, BY TYPE, 2015–2022 (USD MILLION) 69
TABLE 19 MONOVALENT VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 70
TABLE 20 EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET 71
TABLE 21 MULTIVALENT VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 72
TABLE 22 VACCINES MARKET, BY DISEASE INDICATION, 2015–2022 (USD MILLION) 74
TABLE 23 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET 75
TABLE 24 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION,
2015–2022 (USD MILLION) 75
TABLE 25 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET 76
TABLE 26 VACCINES MARKET FOR DTP, BY REGION, 2015–2022 (USD MILLION) 77
TABLE 27 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET 78
TABLE 28 VACCINES MARKET FOR INFLUENZA, BY REGION, 2015–2022 (USD MILLION) 78
TABLE 29 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 79
TABLE 30 VACCINES MARKET FOR HPV, BY REGION, 2015–2022 (USD MILLION) 79
TABLE 31 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 80
TABLE 32 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION,
2015–2022 (USD MILLION) 81
TABLE 33 LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET 82
TABLE 34 VACCINES MARKET FOR POLIO, BY REGION, 2015–2022 (USD MILLION) 82
TABLE 35 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET 83
TABLE 36 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2015–2022 (USD MILLION) 83
TABLE 37 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET 84
TABLE 38 VACCINES MARKET FOR HEPATITIS, BY REGION, 2015–2022 (USD MILLION) 84
TABLE 39 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET 85
TABLE 40 VACCINES MARKET FOR MMR, BY REGION, 2015–2022 (USD MILLION) 85
TABLE 41 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET 86
TABLE 42 VACCINES MARKET FOR VARICELLA, BY REGION, 2015–2022 (USD MILLION) 86
TABLE 43 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS IN THE MARKET 88
TABLE 44 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2015–2022 (USD MILLION) 89
TABLE 45 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015–2022 (USD MILLION) 91
TABLE 46 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2015–2022 (USD MILLION) 92
TABLE 47 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION,
2015–2022 (USD MILLION) 93
TABLE 48 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2015–2022 (USD MILLION) 94
TABLE 49 VACCINES MARKET SIZE, BY END USER, 2015–2022 (USD MILLION) 96
TABLE 50 PEDIATRIC VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 97
TABLE 51 NORTH AMERICA: PEDIATRIC VACCINES MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 98
TABLE 52 ADULT VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 99
TABLE 53 NORTH AMERICA: ADULT VACCINES MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 99
TABLE 54 VACCINES MARKET, BY REGION, 2015–2022 (USD MILLION) 101
TABLE 55 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 103
TABLE 56 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 103
TABLE 57 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2015–2022 (USD MILLION) 103
TABLE 58 NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION,
2015–2022 (USD MILLION) 104
TABLE 59 NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2015–2022 (USD MILLION) 104
TABLE 60 NORTH AMERICA: VACCINES MARKET, BY END USER, 2015–2022 (USD MILLION) 105
TABLE 61 U.S.: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 106
TABLE 62 U.S.: VACCINES MARKET, BY END USER, 2015–2022 (USD MILLION) 106
TABLE 63 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 107
TABLE 64 CANADA: VACCINES MARKET, BY END USER, 2015–2022 (USD MILLION) 107
TABLE 65 EUROPE: VACCINES MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 110
TABLE 66 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 110
TABLE 67 EUROPE: VACCINES MARKET, BY TYPE, 2015–2022 (USD MILLION) 110
TABLE 68 EUROPE: VACCINES MARKET, BY DISEASE INDICATION,
2015–2022 (USD MILLION) 111
TABLE 69 EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2015–2022 (USD MILLION) 111
TABLE 70 EUROPE: VACCINES MARKET, BY END USER, 2015–2022 (USD MILLION) 112
TABLE 71 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 113
TABLE 72 U.K.: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 114
TABLE 73 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 115
TABLE 74 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 115
TABLE 75 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 116
TABLE 76 ROE: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 117
TABLE 77 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 & 2014 (USD) 118
TABLE 78 ASIA: VACCINES MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 120
TABLE 79 ASIA: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 120
TABLE 80 ASIA: VACCINES MARKET, BY TYPE, 2015–2022 (USD MILLION) 120
TABLE 81 ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2015–2022 (USD MILLION) 121
TABLE 82 ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2015–2022 (USD MILLION) 121
TABLE 83 ASIA: VACCINES MARKET, BY END USER, 2015–2022 (USD MILLION) 122
TABLE 84 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 123
TABLE 85 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 124
TABLE 86 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 125
TABLE 87 ROA: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 125
TABLE 88 ROW: VACCINES MARKET, BY TECHNOLOGY, 2015–2022 (USD MILLION) 128
TABLE 89 ROW: VACCINES MARKET, BY TYPE, 2015–2022 (USD MILLION) 128
TABLE 90 ROW: VACCINES MARKET, BY DISEASE INDICATION, 2015–2022 (USD MILLION) 129
TABLE 91 ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2015–2022 (USD MILLION) 129
TABLE 92 ROW: VACCINES MARKET, BY END USER, 2015–2022 (USD MILLION) 129

LIST OF FIGURES

FIGURE 1 VACCINES MARKET SEGMENTATION 18
FIGURE 2 RESEARCH DESIGN 21
FIGURE 3 KEY DATA FROM SECONDARY SOURCES 22
FIGURE 4 KEY DATA FROM PRIMARY SOURCES 23
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 25
FIGURE 6 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 26
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 27
FIGURE 8 DATA TRIANGULATION METHODOLOGY 28
FIGURE 9 VACCINES MARKET, BY TECHNOLOGY, 2017–2022 30
FIGURE 10 VACCINES MARKET, BY TYPE, 2017 VS. 2022 (USD BILLION) 31
FIGURE 11 VACCINES MARKET, BY DISEASE INDICATION, 2017 VS. 2022 (USD BILLION) 31
FIGURE 12 VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2017 VS. 2022 (USD BILLION) 32
FIGURE 13 VACCINES MARKET, BY END USER, 2017 VS. 2022 (USD BILLION) 32
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 33
FIGURE 15 HIGH PREVALENCE OF DISEASES AND RISING GOVERNMENT & NONGOVERNMENT FUNDING FOR VACCINE DEVELOPMENT—PRIMARY GROWTH DRIVERS FOR THE GLOBAL VACCINES MARKET 34
FIGURE 16 MONOVALENT VACCINES TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 35
FIGURE 17 PEDIATRICS SEGMENT WILL CONTINUE TO DOMINATE THE VACCINES MARKET
IN 2022 35
FIGURE 18 CONJUGATE VACCINES TO ACCOUNT FOR THE LARGEST SHARE OF THE VACCINES MARKET IN 2017 36
FIGURE 19 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 37
FIGURE 20 U.S. TO DOMINATE THE VACCINES MARKET IN 2017 37
FIGURE 21 VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
FIGURE 22 MAJOR INVESTORS IN THE GLOBAL VACCINES MARKET 46
FIGURE 23 VACCINE FUNDING, BY INVESTOR, 2014 47
FIGURE 24 GAVI VACCINE FUNDING, BY TYPE OF INVESTOR, 2014 47
FIGURE 25 GAVI FORECAST VACCINE EXPENDITURE, BY DISEASE, 2016–2020 48
FIGURE 26 REGULATORY APPROVAL PROCESS FOR VACCINES 49
FIGURE 27 R&D FUNDING FOR HIV PREVENTIVE VACCINES, BY INVESTOR, 2014 55
FIGURE 28 CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINE TECHNOLOGIES MARKET DURING THE FORECAST PERIOD 61
FIGURE 29 MONOVALENT VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET IN 2017 69
FIGURE 30 PNEUMOCOCCAL DISEASE SEGMENT WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2022 74
FIGURE 31 GLOBAL VACCINES MARKET FOR DENGUE, 2015–2022 (USD MILLION) 87
FIGURE 32 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL VACCINES MARKET IN 2022 91
FIGURE 33 PEDIATRICS END-USER SEGMENT TO DOMINATE THE GLOBAL VACCINES MARKET IN 2017 96
FIGURE 34 NORTH AMERICA: VACCINES MARKET SNAPSHOT, 2017 102
FIGURE 35 EUROPE: VACCINES MARKET SNAPSHOT, 2017 109
FIGURE 36 ASIA: VACCINES MARKET SNAPSHOT, 2017 119
FIGURE 37 ROW: VACCINES MARKET SNAPSHOT, 2017 127
FIGURE 38 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2016 130
FIGURE 39 VACCINES MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2017 133
FIGURE 40 PFIZER, INC.: COMPANY SNAPSHOT 136
FIGURE 41 GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT 141
FIGURE 42 MERCK & CO., INC.: COMPANY SNAPSHOT 146
FIGURE 43 SANOFI PASTEUR SA: COMPANY SNAPSHOT 150
FIGURE 44 CSL LIMITED: COMPANY SNAPSHOT 155
FIGURE 45 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT 159
FIGURE 46 JOHNSON & JOHNSON: COMPANY SNAPSHOT 164
FIGURE 47 ASTRAZENECA: COMPANY SNAPSHOT 168
FIGURE 48 ASTELLAS PHARMA, INC.: COMPANY SNAPSHOT 171
FIGURE 49 BAVARIAN NORDIC: COMPANY SNAPSHOT 177
FIGURE 50 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT 182
FIGURE 51 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT 185
FIGURE 52 PANACEA BIOTEC: COMPANY SNAPSHOT (2016) 193

当レポートのプレスリリースは発行されておりません。